文献速递胃肠外科围术期管理与 ERAS

袖状胃切除、RYGB、BPD-DS与SADI-S术后6个月减重及合并症缓解:基于2023 MBSAQIP数据库的倾向性评分分析

Six-month weight loss and comorbidity remission after sleeve gastrectomy, Roux-en-Y gastric bypass, BPD-DS, and SADI-S: propensity score analysis using the 2023 MBSAQIP database.
PubMed 文献 · Surg Endosc · 2026-09-08

该研究基于2023年MBSAQIP数据库,纳入116195例接受SG、RYGB、BPD-DS或SADI-S的成年患者,经1:1倾向性评分匹配比较6个月结局。结果显示RYGB合并症缓解率高于SG,BPD-DS减重及代谢改善最优,SADI-S减重效果与RYGB相当。

要点

  • RYGB在糖尿病、高血压、高脂血症及GERD缓解率上均优于SG。
  • BPD-DS在减重和糖尿病、高血压缓解方面表现最佳。
  • SADI-S减重效果与RYGB相当,多数合并症缓解率相似。

核心结论

  • 所有评估的减重手术均与6个月体重下降和合并症缓解显著改善相关。
  • RYGB合并症缓解率高于SG,BPD-DS在6个月减重和心血管代谢结局中最优。

研究设计与样本

  • 基于2023年MBSAQIP数据库的倾向性评分匹配分析,纳入18-65岁初次腹腔镜或机器人SG、RYGB、BPD-DS或SADI-S患者。
  • 共纳入116195例:SG 80614例,RYGB 33148例,BPD-DS 1518例,SADI-S 915例。
  • 采用47个术前、术中及术后变量进行六组1:1倾向性评分匹配分析。

主要发现

  • RYGB对比SG:糖尿病缓解64.1% vs 58.1%,高血压41.9% vs 35.8%,高脂血症43.0% vs 37.1%,GERD 55.6% vs 44.9%,%EWL 50.13% vs 43.63%(均p<0.05)。
  • BPD-DS对比SG、RYGB、SADI-S的%EWL分别为52.37% vs 37.73%、52.35% vs 45.92%、51.07% vs 45.02%(均p<0.05)。
  • BPD-DS对比SG、RYGB、SADI-S的糖尿病缓解分别为73.3% vs 59.9%、73.1% vs 65.6%、77.4% vs 66.1%(均p<0.05)。
  • BPD-DS对比SG、RYGB的高血压缓解分别为46.0% vs 31.6%、46.2% vs 37.6%(均p<0.05)。
  • SADI-S对比RYGB的%EWL为44.99% vs 44.73%(p=0.126),多数合并症缓解率相似。

临床怎么用

  • 在追求合并症缓解的减重手术选择中,RYGB可能优于SG。
  • BPD-DS可考虑用于追求最大减重和代谢改善的患者。
  • SADI-S可作为与RYGB减重效果相当的备选术式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bariatric surgery remains the most effective treatment for obesity, yet nationwide bariatric-specific data evaluating early weight loss and comorbidity remission across contemporary procedures are limited. We aimed to compare 6-month outcomes after sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD-DS), and single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). METHODS: We analyzed adults aged 18-65 years who underwent primary laparoscopic or robotic SG, RYGB, BPD-DS, or SADI-S in the 2023 MBSAQIP database with available long-term follow-up PUF data. Six pairwise 1:1 propensity score-matched analyses were performed using 47 preoperative, intraoperative, and postoperative variables. Outcomes included 6-month weight loss and remission of diabetes, hypertension, hyperlipidemia, sleep apnea, and gastroesophageal reflux disease (GERD). RESULTS: A total of 116,195 patients were included: 80,614 SG, 33,148 RYGB, 1518 BPD-DS, and 915 SADI-S. Compared with SG, RYGB showed higher remission of diabetes (64.1% vs. 58.1%), hypertension (41.9% vs. 35.8%), hyperlipidemia (43.0% vs. 37.1%), and GERD (55.6% vs. 44.9%), as well as greater %EWL (50.13% vs. 43.63%) (all p < 0.05). Among all procedures, BPD-DS achieved the greatest weight-loss outcomes, with higher %EWL than SG (52.37% vs. 37.73%), RYGB (52.35% vs. 45.92%), and SADI-S (51.07% vs. 45.02%) (all p < 0.05). BPD-DS also showed greater metabolic benefits, including higher diabetes remission than SG (73.3% vs. 59.9%), RYGB (73.1% vs. 65.6%), and SADI-S (77.4% vs. 66.1%), as well as higher hypertension remission than SG (46.0% vs. 31.6%) and RYGB (46.2% vs. 37.6%) (all p < 0.05). Finally, SADI-S showed a similar weight-loss profile to RYGB, with no significant difference in %EWL (44.99% vs. 44.73%, p = 0.126), and comparable remission rates for most evaluated comorbidities. CONCLUSION: In our national propensity-matched analysis, all evaluated bariatric procedures were associated with significant improvements in weight loss and comorbidity remission. However, RYGB demonstrated higher remission rates than SG, whereas BPD-DS achieved the most favorable 6-month weight-loss and cardiometabolic outcomes among all procedures.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Sebastian R, Tuesta O, Riva A, et al. Six-month weight loss and comorbidity remission after sleeve gastrectomy, Roux-en-Y gastric bypass, BPD-DS, and SADI-S: propensity score analysis using the 2023 MBSAQIP database. Surg Endosc. 2026. PMID: 42711587. doi:10.1007/s00464-026-13311-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。